DYNAVAX TECHNOLOGIES CORPDVAXEarnings & Financial Report
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
DVAX Q3 FY2025 Key Financial Metrics
Revenue
$94.9M
Gross Profit
N/A
Operating Profit
$21.3M
Net Profit
$26.9M
Gross Margin
N/A
Operating Margin
22.4%
Net Margin
28.4%
YoY Growth
17.7%
EPS
$0.21
DYNAVAX TECHNOLOGIES CORP Q3 FY2025 Financial Summary
DYNAVAX TECHNOLOGIES CORP reported revenue of $94.9M (up 17.7% YoY) for Q3 FY2025, with a net profit of $26.9M (up 53.0% YoY) (28.4% margin).
Key Financial Metrics
| Total Revenue | $94.9M |
|---|---|
| Net Profit | $26.9M |
| Gross Margin | N/A |
| Operating Margin | 22.4% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
DYNAVAX TECHNOLOGIES CORP Q3 FY2025 revenue of $94.9M breaks down across 2 segments, led by HEPLISAVB at $90.0M (94.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| HEPLISAVB | $90.0M | 94.8% |
| US Department Of Defense | $4.7M | 5.0% |
DYNAVAX TECHNOLOGIES CORP Revenue by Segment — Quarterly Trend
DYNAVAX TECHNOLOGIES CORP revenue by segment across the last 4 reported quarters, showing how each business line (such as HEPLISAVB and US Department Of Defense) has evolved quarter over quarter.
| Segment | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|
| HEPLISAVB | $90.0M | — | $65.0M | — |
| US Department Of Defense | $4.7M | — | — | $900.0K |
DYNAVAX TECHNOLOGIES CORP Annual Revenue by Year
DYNAVAX TECHNOLOGIES CORP annual revenue history includes year-by-year totals (for example, 2024 revenue was $277.2M).
DYNAVAX TECHNOLOGIES CORP Quarterly Revenue & Net Profit History
DYNAVAX TECHNOLOGIES CORP results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $94.9M | +17.7% | $26.9M | 28.4% |
| Q2 FY2025 | $95.4M | +29.3% | $18.7M | 19.6% |
| Q1 FY2025 | $68.2M | +34.2% | $-96.1M | -141.0% |
| Q4 FY2024 | $72.0M | +29.6% | $7.0M | 9.8% |
| Q3 FY2024 | $80.6M | +16.0% | $17.6M | 21.8% |
| Q2 FY2024 | $73.8M | +22.5% | $11.4M | 15.4% |
| Q1 FY2024 | $50.8M | +8.2% | $-8.7M | -17.2% |
| Q4 FY2023 | $55.6M | -69.9% | $219.0K | 0.4% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $55.6M | $50.8M | $73.8M | $80.6M | $72.0M | $68.2M | $95.4M | $94.9M |
| YoY Growth | -69.9% | 8.2% | 22.5% | 16.0% | 29.6% | 34.2% | 29.3% | 17.7% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $997.1M | $986.6M | $1.02B | $1.06B | $986.3M | $945.9M | $918.4M | $946.5M |
| Liabilities | $375.0M | $368.1M | $373.5M | $380.6M | $389.5M | $415.0M | $424.3M | $412.4M |
| Equity | $622.1M | $618.5M | $642.8M | $681.4M | $596.8M | $530.9M | $494.2M | $534.1M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $13.8M | $-16.7M | $10.7M | $19.5M | $53.0M | $-19.6M | $23.4M | $33.8M |